David Moatazedi Sells 105,108 Shares of Evolus (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 105,108 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $9.04, for a total transaction of $950,176.32. Following the completion of the sale, the insider directly owned 499,592 shares in the company, valued at approximately $4,516,311.68. This represents a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Evolus Stock Up 2.8%

Shares of NASDAQ EOLS opened at $9.30 on Friday. Evolus, Inc. has a twelve month low of $3.86 and a twelve month high of $9.31. The firm has a fifty day simple moving average of $7.26 and a 200 day simple moving average of $6.08. The company has a market capitalization of $614.26 million, a PE ratio of -17.88 and a beta of 1.42.

Institutional Trading of Evolus

Several hedge funds have recently bought and sold shares of EOLS. Larson Financial Group LLC raised its holdings in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after buying an additional 2,837 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Evolus during the fourth quarter worth about $34,000. California State Teachers Retirement System increased its position in shares of Evolus by 79.9% during the second quarter. California State Teachers Retirement System now owns 5,455 shares of the company’s stock worth $38,000 after acquiring an additional 2,423 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Evolus in the 2nd quarter worth about $40,000. Finally, Wexford Capital LP acquired a new stake in shares of Evolus in the 3rd quarter worth about $37,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Wall Street Zen raised Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. BTIG Research restated a “buy” rating and set a $13.00 price target on shares of Evolus in a report on Wednesday, June 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Tuesday, August 25th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $14.50.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.